Cytek Biosciences Inc. (CTKB)
Cytek Biosciences Inc. (CTKB) Stock Price, Analysis & Data
| Bid | 3.53 |
| Market Cap | 610.92M |
| Revenue (ttm) | 206.71M |
| Net Income (ttm) | -80.58M |
| Beta | 1.17 |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | n/a |
| Forward PE | 67.14 |
| P/B (ttm) | 1.90 |
| P/S (ttm) | 2.96 |
| Earnings Date | Sep 2, 2021 |
| Ask | 6 |
| Volume | 872,970 |
| Avg. Volume (20D) | 1,332,262 |
| Open | 4.67 |
| Previous Close | 4.67 |
| Day's Range | 4.67 - 4.92 |
| 52-Week Range | 3.28 - 6.18 |
| Analyst | Buy |
| Price Target | 5 (6.38%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle d...
Financial Performance
In 2025, Cytek Biosciences's revenue was 201.49M, an increase of 0.52% compared to the previous year's 200.45M. Earnings were -66.54M, an increase of 1,005.3%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for CTKB stock is "Buy". The 12-month stock price forecast is 5, which is upside of 6.38% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
